NCT04055753 2024-12-04
Study to Assess TOPO2A as a Biomarker for Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
Fox Chase Cancer Center
Active not recruiting
Clinical Trials
8 trialsNCT05976932 2023-08-04
Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer
Fudan University
Unknown
NCT04258163 2020-02-10
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Completed
NCT03562533 2019-02-28
Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer
Konkuk University Medical Center
Completed
NCT03367182 2019-01-11
REBECA
Yonsei University
Completed
NCT03419494 2018-02-05
Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Unknown
NCT00743431 2015-04-15
Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)
Merck Sharp & Dohme LLC
Completed
NCT00736333 2014-11-05
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)
Merck Sharp & Dohme LLC
Completed